Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICADNYSE:INFUNASDAQ:NMTCNASDAQ:OBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICADiCAD$3.83+4.9%$2.99$1.18▼$4.02$105.49M1.35412,243 shs558,489 shsINFUInfuSystem$5.78+3.2%$5.25$4.61▼$9.97$121.47M1.7396,696 shs166,410 shsNMTCNeuroOne Medical Technologies$0.61-3.7%$0.62$0.40▼$1.39$30.61M0.65182,673 shs88,138 shsOBIOOrchestra BioMed$2.85+0.7%$2.94$2.37▼$8.87$109.19M0.67164,862 shs104,264 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICADiCAD0.00%+2.68%+11.99%+58.92%+151.97%INFUInfuSystem0.00%+6.84%+21.68%-27.57%-23.04%NMTCNeuroOne Medical Technologies0.00%-1.36%-0.58%-44.90%-37.62%OBIOOrchestra BioMed0.00%+4.78%+3.64%-39.23%-59.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICADiCAD0.442 of 5 stars0.03.00.00.02.60.80.0INFUInfuSystem2.7283 of 5 stars2.00.00.00.03.74.21.9NMTCNeuroOne Medical Technologies2.5703 of 5 stars3.55.00.00.01.71.70.0OBIOOrchestra BioMed2.9272 of 5 stars4.64.00.00.01.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICADiCAD 2.00HoldN/AN/AINFUInfuSystem 4.00Strong Buy$13.00124.91% UpsideNMTCNeuroOne Medical Technologies 3.00Buy$1.45136.00% UpsideOBIOOrchestra BioMed 3.20Buy$14.20398.25% UpsideCurrent Analyst Ratings BreakdownLatest NMTC, OBIO, INFU, and ICAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025NMTCNeuroOne Medical TechnologiesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.455/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/17/2025ICADiCADLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/16/2025ICADiCADBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/16/2025ICADiCADCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.004/3/2025OBIOOrchestra BioMedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICADiCAD$19.53M5.39N/AN/A$1.27 per share3.02INFUInfuSystem$137.58M0.88$0.45 per share12.79$2.47 per share2.34NMTCNeuroOne Medical Technologies$5.76M5.32N/AN/A$0.10 per share6.14OBIOOrchestra BioMed$2.89M37.84N/AN/A$1.90 per share1.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICADiCAD-$4.85M-$0.19N/A∞N/A-17.81%-15.65%-12.52%8/11/2025 (Estimated)INFUInfuSystem$870K$0.1496.3518.65N/A1.12%2.78%1.41%N/ANMTCNeuroOne Medical Technologies-$12.32M-$0.22N/A∞N/A-82.17%-270.70%-129.70%8/13/2025 (Estimated)OBIOOrchestra BioMed-$49.12M-$1.78N/AN/AN/A-2,179.33%-107.04%-70.88%N/ALatest NMTC, OBIO, INFU, and ICAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ICADiCAD-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million5/13/2025Q2 2025NMTCNeuroOne Medical Technologies-$0.09-$0.07+$0.02-$0.07$1.27 billion$1.39 billion5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 million3/19/2025Q4 2024ICADiCAD-$0.0525-$0.03+$0.0225-$0.03$4.72 million$5.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICADiCADN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICADiCADN/A4.023.91INFUInfuSystem0.501.981.59NMTCNeuroOne Medical TechnologiesN/A3.642.41OBIOOrchestra BioMedN/A4.234.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICADiCAD24.61%INFUInfuSystem71.13%NMTCNeuroOne Medical Technologies16.07%OBIOOrchestra BioMed53.55%Insider OwnershipCompanyInsider OwnershipICADiCAD10.29%INFUInfuSystem11.40%NMTCNeuroOne Medical Technologies8.90%OBIOOrchestra BioMed8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICADiCAD14027.47 million23.81 millionOptionableINFUInfuSystem41021.02 million19.10 millionOptionableNMTCNeuroOne Medical Technologies2049.82 million28.12 millionOptionableOBIOOrchestra BioMed438.31 million35.47 millionNot OptionableNMTC, OBIO, INFU, and ICAD HeadlinesRecent News About These CompaniesOrchestra BioMed: Two Best-In-Class Devices And Promising PartnershipsMay 28, 2025 | seekingalpha.comHead to Head Contrast: SeaStar Medical (NASDAQ:ICU) vs. Orchestra BioMed (NASDAQ:OBIO)May 24, 2025 | americanbankingnews.comOrchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comOrchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative OptimismMay 14, 2025 | seekingalpha.comOrchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comOrchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical MilestonesMay 12, 2025 | globenewswire.comOrchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough DesignationMay 11, 2025 | msn.comOrchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global PatentsMay 9, 2025 | nasdaq.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%May 9, 2025 | aaii.comOrchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 8, 2025 | finance.yahoo.comBarclays Has Lowered Expectations for Orchestra BioMed (NASDAQ:OBIO) Stock PriceMay 7, 2025 | marketbeat.comOrchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 7, 2025 | globenewswire.comOrchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 5, 2025 | zacks.comBoxer Capital Management LLC Makes New $953,000 Investment in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)May 4, 2025 | marketbeat.comOrchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR TreatmentMay 1, 2025 | msn.comOrchestra BioMed to Present at Jefferies Global Healthcare ConferenceMay 1, 2025 | msn.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%May 1, 2025 | aaii.comFDA approves head-to-head trial of Orchestra BioMed’s balloonApril 30, 2025 | investing.comOrchestra BioMed wins FDA IDE for sirolimus-angioballoonApril 29, 2025 | massdevice.comOrchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated BalloonApril 29, 2025 | globenewswire.comOrchestra BioMed to Participate in Upcoming Institutional Investor ConferencesApril 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock By Jeffrey Neal Johnson | May 28, 2025View Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock NMTC, OBIO, INFU, and ICAD Company DescriptionsiCAD NASDAQ:ICAD$3.83 +0.18 (+4.93%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.83 0.00 (0.00%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.InfuSystem NYSE:INFU$5.78 +0.18 (+3.21%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.78 0.00 (0.00%) As of 05/30/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.NeuroOne Medical Technologies NASDAQ:NMTC$0.61 -0.02 (-3.74%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.62 +0.01 (+1.73%) As of 05/30/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Orchestra BioMed NASDAQ:OBIO$2.85 +0.02 (+0.71%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.85 0.00 (0.00%) As of 05/30/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
